Literature DB >> 14529542

Novel inhibitors of HIV integrase: the discovery of potential anti-HIV therapeutic agents.

Vasu Nair1.   

Abstract

The viral enzyme, HIV integrase (MW 32 kDa), is one of the three key enzymes of the pol gene of HIV. HIV integrase is involved in the integration of HIV DNA into host chromosomal DNA. There is apparently no functional equivalent of this enzyme in human cells. Integration of HIV DNA into the host cell genome apparently occurs by a carefully defined sequence of DNA tailoring (3'-processing) and coupling (joining or integration) reactions. In spite of some effort in this area targeted at the discovery of therapeutically useful inhibitors of this viral enzyme, there are no drugs for HIV/AIDS in clinical use where the mechanism of action is inhibition of HIV integrase. It is clear that new knowledge on inhibitors of this enzyme is of critical importance in the anti-HIV drug discovery area. This review focuses on the major classes of compounds that have been discovered as inhibitors of HIV integrase. Some of these compounds are non-specific inhibitors of the enzyme while evidence suggests that others may possess some specificity. The various classes include nucleotides, oligonucleotides, dinucleotides, and miscellaneous small molecules including heterocyclic systems, natural products, diketo acids and sulfones. A major focus of the review is on discoveries from my laboratory in the area of non-natural, nuclease-resistant dinucleotide inhibitors of HIV integrase.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529542     DOI: 10.2174/1381612033453703

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

1.  HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent.

Authors:  Vasu Nair; Guochen Chi; Roger Ptak; Nouri Neamati
Journal:  J Med Chem       Date:  2006-01-26       Impact factor: 7.446

2.  Discovery of a Potent HIV Integrase Inhibitor that Leads to a Prodrug with Significant anti-HIV Activity.

Authors:  Byung I Seo; Vinod R Uchil; Maurice Okello; Sanjay Mishra; Xiao-Hui Ma; Malik Nishonov; Qingning Shu; Guochen Chi; Vasu Nair
Journal:  ACS Med Chem Lett       Date:  2011-10-05       Impact factor: 4.345

3.  Binding modes of diketo-acid inhibitors of HIV-1 integrase: a comparative molecular dynamics simulation study.

Authors:  Meilan Huang; Guy H Grant; W Graham Richards
Journal:  J Mol Graph Model       Date:  2011-04-09       Impact factor: 2.518

Review 4.  Nanotechnology: intelligent design to treat complex disease.

Authors:  Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.580

Review 5.  Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids.

Authors:  Vasu Nair; Maurice Okello
Journal:  Molecules       Date:  2015-07-13       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.